Carcinosarcoma of the nasal cavity and paranasal sinuses: Review of the national cancer database

Background Carcinosarcomas are rare, aggressive malignancies that can arise in the nasal cavity and paranasal sinuses. There are limited outcome data available. Accordingly, we sought to use the National Cancer Database (NCDB) to characterize patient demographics and outcomes. Method A retrospective...

Full description

Saved in:
Bibliographic Details
Published in:World journal of otorhinolaryngology - head and neck surgery 2023-06, Vol.9 (2), p.115-122
Main Authors: Harris, Jacob C., Eide, Jacob G., Kshirsagar, Rijul S., Brant, Jason A., Palmer, James N., Adappa, Nithin D.
Format: Article
Language:English
Subjects:
Age
cancer
Cancer therapies
carcinosarcoma
Case reports
Chemotherapy
Comorbidity
Demographics
Endoscopy
Histology
Hospitals
Length of stay
Medicaid
Medical prognosis
Medicare
National Cancer Database
NCDB
outcomes
Patients
Radiation therapy
Review
sinonasal
Sinuses
Statistical analysis
Surgery
survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Carcinosarcomas are rare, aggressive malignancies that can arise in the nasal cavity and paranasal sinuses. There are limited outcome data available. Accordingly, we sought to use the National Cancer Database (NCDB) to characterize patient demographics and outcomes. Method A retrospective analysis of the NCDB from 2004 to 2016 for patients with sinonasal carcinosarcoma was conducted. Results Thirty patients were included. The patients were predominantly male (n = 20), white (n = 23), and privately insured (n = 15), with an average age of 62.4 years. The nasal cavity was the most common subsite (n = 14), followed by the maxillary sinus (n = 8). Most patient were treated with surgery followed by radiation (n = 23), with the remaining undergoing surgery alone (n = 4), radiation alone (n = 2), or no treatment (n = 1). One‐third (n = 10) received adjuvant chemotherapy. The 1‐ and 5‐year overall survival (OS) in the cohort were 79.2% and 43.3%, respectively. Univariate log‐rank testing showed OS varied based on intervention (P 
ISSN:2095-8811
2589-1081
DOI:10.1002/wjo2.82